Sei Investments Co. Acquires 169,906 Shares of Novo Nordisk A/S $NVO

Sei Investments Co. boosted its holdings in Novo Nordisk A/S (NYSE:NVO) by 53.7% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 486,550 shares of the company’s stock after purchasing an additional 169,906 shares during the period. Sei Investments Co.’s holdings in Novo Nordisk A/S were worth $17,882,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Quotient Wealth Partners LLC boosted its stake in shares of Novo Nordisk A/S by 2.0% during the 4th quarter. Quotient Wealth Partners LLC now owns 9,091 shares of the company’s stock worth $463,000 after buying an additional 177 shares during the last quarter. Certuity LLC grew its holdings in shares of Novo Nordisk A/S by 3.6% in the 4th quarter. Certuity LLC now owns 5,052 shares of the company’s stock valued at $257,000 after acquiring an additional 177 shares in the last quarter. Oakworth Capital Inc. increased its position in shares of Novo Nordisk A/S by 41.6% in the fourth quarter. Oakworth Capital Inc. now owns 619 shares of the company’s stock valued at $31,000 after acquiring an additional 182 shares during the last quarter. True North Advisors LLC raised its holdings in Novo Nordisk A/S by 3.9% during the fourth quarter. True North Advisors LLC now owns 5,305 shares of the company’s stock worth $270,000 after acquiring an additional 199 shares in the last quarter. Finally, Asio Capital LLC raised its holdings in Novo Nordisk A/S by 3.9% during the fourth quarter. Asio Capital LLC now owns 5,386 shares of the company’s stock worth $274,000 after acquiring an additional 200 shares in the last quarter. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

NVO has been the subject of a number of analyst reports. Nordea Equity Research upgraded Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research note on Friday, June 19th. Zacks Research cut Novo Nordisk A/S from a “hold” rating to a “strong sell” rating in a research note on Monday, July 13th. HSBC reissued a “hold” rating on shares of Novo Nordisk A/S in a report on Monday, July 6th. Wall Street Zen downgraded shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a report on Saturday, June 20th. Finally, Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Novo Nordisk A/S in a research report on Monday, July 20th. Five analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $65.56.

Novo Nordisk A/S Stock Up 1.2%

NVO stock opened at $51.56 on Thursday. The company has a current ratio of 0.79, a quick ratio of 0.56 and a debt-to-equity ratio of 0.59. The firm has a market capitalization of $230.22 billion, a PE ratio of 12.10, a PEG ratio of 4.65 and a beta of 0.77. Novo Nordisk A/S has a 1-year low of $35.12 and a 1-year high of $64.16. The business’s 50 day simple moving average is $46.73 and its 200 day simple moving average is $45.54.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings results on Tuesday, March 31st. The company reported $1.03 earnings per share (EPS) for the quarter. Novo Nordisk A/S had a return on equity of 63.31% and a net margin of 37.23%.The business had revenue of $10.85 billion during the quarter. As a group, research analysts anticipate that Novo Nordisk A/S will post 3.39 EPS for the current year.

Trending Headlines about Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo Nordisk partnered with Crux to make Wegovy and other GLP-1 obesity treatments more accessible through U.S. employer health plans. Simpler benefit structures and more predictable pricing could broaden coverage and support demand. Novo Nordisk Teams Up With Crux To Expand Wegovy Access
• Positive Sentiment: The European Commission’s authorization of a once-daily oral Wegovy pill, combined with the U.S. access agreement, strengthens Novo Nordisk’s obesity-treatment portfolio. An oral option could improve patient convenience and expand the addressable market, although commercial uptake remains to be demonstrated. Novo Nordisk Is Up After EU Wegovy Pill Approval And US Access Deal
• Neutral Sentiment: Investors are watching upcoming second-quarter results for evidence that Ozempic and Wegovy sales, oral-product launches and label expansions can sustain growth despite intensifying competition. Strong results or guidance could support the shares, while signs of slowing momentum could weigh on them. How Will Ozempic and Wegovy Sales Aid NVO’s Upcoming Q2 Results?
• Negative Sentiment: A U.S. judge allowed parts of a shareholder lawsuit alleging Novo Nordisk misled investors about a clinical trial for CagriSema to proceed. The case could create legal costs and reputational damage, while raising concerns about disclosures surrounding a key future growth product. Why Shareholders Are Suing Novo Nordisk Over CagriSema

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.